Ownership and insider activity for Rallybio Corporation (RLYB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Price
| Price | $17.09 |
| Market Cap | $91M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.5M | $140.2M | $175.3M | $57.0M | $24.5M | $13.9M | $31.4M |
| Short-term Investments | 0 | 0 | 0 | $112.0M | $85.4M | $51.6M | $23.4M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $20.9M | $141.3M | $180.9M | $179.5M | $114.8M | $67.8M | $61.3M |
| Property, Plant & Equipment | $199000 | $287000 | $511000 | $909000 | $592000 | $267000 | $198000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $21.6M | $141.9M | $182.2M | $180.4M | $115.6M | $68.1M | $62.3M |
| Accounts Payable | $857000 | $1.6M | $603000 | $1.1M | $976000 | $278000 | $126000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.8M | $5.8M | $6.6M | $10.7M | $9.3M | $6.2M | $4.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $4.7M | $5.9M | $6.6M | $11.1M | $9.4M | $6.5M | $4.3M |
| Retained Earnings | -$20.6M | -$47.0M | -$94.0M | -$160.7M | -$235.2M | -$293.0M | -$302.0M |
| Total Equity | $16.9M | $136.0M | $175.6M | $169.3M | $106.2M | $61.7M | $58.0M |
| Total Debt | 0 | 0 | 0 | $555000 | $392000 | $154000 | $176000 |
| Net Debt | -$19.5M | -$140.2M | -$175.3M | -$168.4M | -$109.5M | -$65.4M | -$54.6M |
| Working Capital | $17.1M | $135.4M | $174.3M | $168.8M | $105.5M | $61.6M | $57.0M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 27.26 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.86 |
Profitability
| Return on Equity | 68.56% |
| Return on Invested Capital | -24.40% |
| Return on Assets | 46.45% |
| Gross Margin | -1107.59% |
| Operating Margin | -3672.29% |
| Net Margin | 7051.24% |
Related companies: BOLD · CVKD · IBIO · INTS · ITRM · KLTO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of RLYB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks